Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q2 2021 Earnings Presentation
15 slides from Expres2ion Biotech Holding Ab's earnings presentation, Aug 19, 2021
Slide 1: Presentation of Q2 2021 results
Presentation of Q2 2021 results August 19, 2021 Proteins for Life Bent U. Frandsen, CEO
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this pre
Slide 3: Leader in advanced protein sciences with novel pipeline addressing 45B EUR markets
Leader in advanced protein sciences with novel pipeline addressing 45B EUR markets Proven leader in the production of complex proteins with our proprietary ExpreS2 technology, used in therapeutics, vaccines, and diagnostics, with >100 clients worldwide AdaptVac, our joint venture with NextGen, combi
Slide 4: Broad clinical stage pipeline
Broad clinical stage pipeline Addressing high medical needs with development partner potential DISEASE Project / Target Discovery Pre-clinical cGMP / Tox Phase 1 Phase 2 Phase 3 Market Pharmacology potential Partners / Funding > 30 Corona virus ABNCoV2/SARS-CoV-2 cVLP I / II BN: II PREVENT-nCOV bill
Slide 5: Progress during Quarter 2 2021
nd Progress during 2 Quarter 2021 CORONAVIRUS/COVID-19 April 12 First group of August 9 Phase I/II headline safety volunteers in Phase I/II study and efficacy results. Excellent virus satisfactorily administered with neutralization including for vaccine. No untoward safety relevant COVID-19 variants
Slide 6: HER2+ Breast Cancer Overview
BREAST CANCER HER2+ Breast Cancer Overview Over 180,000 people diagnosed with HER2+ breast Monoclonal antibodies are the cornerstone of treatment cancer per year across US, EU, & Japan1,2 for HER2+ breast cancer (>$7B USD sales) • Target the HER2 receptor on tumor cells to reduce proliferation and i
Slide 7: COVID-19 license and JV economics
CORONAVIRUS COVID-19 license and JV economics AdaptVac’s Economics ExpreS2ion’s Economics Paid by Bavarian Nordic Paid by AdaptVac • 4 MEUR upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to 136 MEUR in development and • Up to 2 MEUR in commercial milestone sales milestones payments • S
Slide 8: Q2-2021 Report
Q2-2021 Report Proteins for Life 8
Slide 9: Half-Year Report 2021: A word from our CEO
Q2-2021 Report EXPRES2ION HALF-YEAR REPORT 2021 “I am exceedingly proud of the major accomplishments Half-Year Report 2021 A word from achieved by ExpreS2ion in 2020, both from a global health perspective and when it comes to building strong Proteins our CEO long-term value for our shareholders. Our
Slide 10: Summary of Q2 interim results
Summary of Q2 interim results Second quarter (April – June 2021) First half (January – June 2021) • Operating income amounted to 4,793 (4,016) KSEK. • Operating income amounted to 6,724 (6,845) KSEK. • Profit/loss after financial items amounted to -10,136 (-4,953) KSEK. • Profit/loss after financial
Slide 11: 2Q21 - Key Financial Developments
2Q21 - Key Financial Developments Operating income, SEK ‘000s Operating profit (loss), SEK ‘000s Cash, SEK millions 6,000 0 120 5,000 -3,000 100 4,000 -6,000 80 3,000 -9,000 60 2,000 -12,000 40 1,000 -15,000 20 0 1Q19 3Q19 1Q20 3Q20 1Q21 -18,000 0 Non-Grant Grant 1Q19 3Q19 1Q20 3Q20 1Q21 1Q19 3Q19 1
Slide 12: Income statement
Income statement Group KS E K Q2 2021 Q2 2020 % c ha nge H 1 2021 H 1 2020 % c ha nge F Y 2020 O pe ra t ing inc o m e Net sales 4,584 1,545 197% 6,288 3,768 67% 5,259 Other o perating inco me 209 2,471 -92% 436 3,077 -86% 10,004 T o t a l o pe ra t ing inc o m e 4 ,7 9 3 4 ,0 16 19 % 6 ,7 2 4 6 ,8
Slide 13: Research Analysts / Investor Relations
Research Analysts / Investor Relations September conference Institutional In dialogue with larger financial June conference institutions Blend SEK 66 target Retail Active message boards IR/Social Media Aktiespararna September conference September conference SEK 49 target and September Aktiedagen Pro
Slide 14: 2021 – 2023 Outlook
2021 – 2023 Outlook Proteins for Life 14
Slide 15: Proteins for Life
Proteins for Life 19th August, 2021 Q2-2021 Report Bent U. Frandsen, CEO Keith Alexander, CFO
ExpreS2ion Biotech Holding — Q2 2021 Earnings Presentation on 6ix